Literature DB >> 28691941

Extraintestinal Manifestations Are Common in Obese Patients with Crohn's Disease.

Manish B Singla1, Christa Eickhoff, John Betteridge.   

Abstract

INTRODUCTION: Crohn's disease (CD) is a chronic condition associated with the risk of malabsorption. The incidence of obesity worldwide is increasing, and the effect of obesity on patients with CD is unknown. We aim to identify traits related to obesity in a cohort of patients with CD.
METHODS: We conducted a retrospective study of 209 adult patients with CD. Age, Montreal disease classification, sex, race, duration of disease, erythrocyte sedimentation rate, C-reactive protein levels, physician global assessment, endoscopic appearance, histologic activity, medication use, and body mass index (BMI) were collected about each patient.
RESULTS: The mean age was 43.4 ± 14.9 years; 68.9% were white, and 51.7% were male. The mean duration of disease was 11.0 ± 10.6 years. The mean BMI was 26.8 ± 5.7: underweight 7.7%; normal weight 29.3%; overweight 38.0%; and obese 25%. Patients with higher BMI were more likely to have extraintestinal manifestations (EIM) (P = 0.005) and more likely to have nonarthralgia extraintestinal manifestations (P = 0.047). There was a linear association between proximal CD and decreasing BMI (underweight 31.3%, normal weight 14.8%, overweight 15.0%, obese 7.7%; P = 0.046). There was no difference in BMI between patients with and without perianal disease (P = 0.216).
CONCLUSIONS: Most patients were overweight or obese, which correlates with national population trends. Our data suggest disease location plays a role in weight modulation in patients with CD. Increased extraintestinal manifestations in patients with high BMI suggests that the chronic inflammation associated with obesity may play a role in extraintestinal inflammation.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28691941     DOI: 10.1097/MIB.0000000000001187

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  6 in total

1.  Impact of Bariatric Surgery on the Long-term Disease Course of Inflammatory Bowel Disease.

Authors:  Manuel B Braga Neto; Martin H Gregory; Guilherme P Ramos; Fateh Bazerbachi; David H Bruining; Barham K Abu Dayyeh; Vladimir M Kushnir; Laura E Raffals; Matthew A Ciorba; Edward V Loftus; Parakkal Deepak
Journal:  Inflamm Bowel Dis       Date:  2020-06-18       Impact factor: 5.325

2.  Impact of Obesity on Short- and Intermediate-Term Outcomes in Inflammatory Bowel Diseases: Pooled Analysis of Placebo Arms of Infliximab Clinical Trials.

Authors:  Siddharth Singh; James Proudfoot; Ronghui Xu; William J Sandborn
Journal:  Inflamm Bowel Dis       Date:  2018-09-15       Impact factor: 5.325

3.  Impact of Obesity on Disease Activity and Patient-Reported Outcomes Measurement Information System (PROMIS) in Inflammatory Bowel Diseases.

Authors:  Animesh Jain; Nghia H Nguyen; James A Proudfoot; Christopher F Martin; William J Sandborn; Michael D Kappelman; Millie D Long; Siddharth Singh
Journal:  Am J Gastroenterol       Date:  2019-04       Impact factor: 10.864

Review 4.  Impact of Obesity on Inflammatory Bowel Disease.

Authors:  Nidah Shabbir Khakoo; Stephanie Ioannou; Nabiha Shabbir Khakoo; Shyam Vedantam; Michelle Pearlman
Journal:  Curr Gastroenterol Rep       Date:  2022-02-12

Review 5.  Role of Obesity, Mesenteric Adipose Tissue, and Adipokines in Inflammatory Bowel Diseases.

Authors:  Jan Bilski; Agnieszka Mazur-Bialy; Dagmara Wojcik; Marcin Surmiak; Marcin Magierowski; Zbigniew Sliwowski; Robert Pajdo; Slawomir Kwiecien; Aleksandra Danielak; Agata Ptak-Belowska; Thomas Brzozowski
Journal:  Biomolecules       Date:  2019-11-26

6.  Prevalence of extraintestinal manifestations in Korean inflammatory bowel disease patients.

Authors:  Bo Ram Yang; Nam-Kyong Choi; Mi-Sook Kim; Jaeyoung Chun; Sang Hyun Joo; Hyesung Kim; Joongyub Lee
Journal:  PLoS One       Date:  2018-07-10       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.